Restatement of Previously Issued Consolidated Financial Statements (Tables)

12 Months Ended

Dec. 31, 2021

Condensed Financial Information Disclosure [Abstract]

Schedule of consolidated balance sheet

	As of December 31, 2021
$ in thousands	As Reported			Adjustments			As Restated
Contract loss provisions	$	5,180		$	(4,783	)	$	397
Total current liabilities		17,312			(4,783	)		12,529
Total liabilities		48,173			(4,783	)		43,390
Accumulated deficit		(171,363	)		4,783			(166,580	)
Total shareholders’ equity		209,275			4,783			214,058

Schedule of consolidated statement of operations

	Year ended December 31, 2021
$ in thousands, except per share data	As Reported			Adjustments			As Restated
Revenue:
Sales revenue	$	8,804		$	(1,442	)	$	7,362
Grant revenue		—			1,442			1,442
Total revenue		8,804			—			8,804
Cost of revenue:
Cost of revenue		7,203			(1,441	)		5,762
Cost of grant revenue		—			3,177			3,177
Provision for contract losses		6,485			(5,977	)		508
Total cost of revenue		13,688			(4,241	)		9,447
Gross loss		(4,884	)		4,241			(643	)
Selling, general, and administrative		30,386			(542	)		29,844
Total operating expenses		43,864			(542	)		43,322
Operating loss		(48,748	)		4,783			(43,965	)
Net loss before taxes		(142,189	)		4,783			(137,406	)
Net loss		(142,191	)		4,783			(137,408	)
Total comprehensive loss	$	(142,195	)	$	4,783		$	(137,412	)
Loss per share – Basic and Diluted		(11.88	)		0.40			(11.48	)

Schedule of consolidated statement of cash flows

	Year ended December 31, 2021
$ in thousands	As Reported			Adjustments			As Restated
Cash flows from operating activities:
Net Loss	$	(142,191	)	$	4,783		$	(137,408	)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for contract losses, net		5,180			(4,783	)		397